IMS 2026 | Revisiting complete response criteria with mass spectrometry in multiple myeloma

So that paper tried to integrate or to know how to integrate mass spectrometry in the current framework of assessing the presence of the monoclonal protein in patients with monoclonal gammopathy and specifically in the framework of response assessment. So basically what I can say about that is that, so we see a proportion of patients that are in CR, or at least they have a negative immune fixation and they are positive using mass spectrometry. These patients do worse. So I think these patients have to be captured using mass spectrometry. So to integrate mass spectrometry in that framework, what I think is that so at the higher levels of residual disease that is in partial response so I think the correlation can be direct so you know we are going to get similar results using both methodologies so the more difficult part comes from very good partial response to immune fixation – very good partial response based on the 90% reduction of the monoclonal protein in serum and very good partial response based on the immune fixation. So we have to define the correlation with mass spectrometry at those lower levels of disease. And that level of disease, I would say, is where we need to work to define the good correlation because, you know, we can identify and quantify the monoclonal protein at those very low levels that I’m commenting previously with the standard methods. So we can quantify. And so what I would say is that we need to get those results and then once we have them all using mass spectrometry we can get a quantity and then we have to reassess them and define so what is the new category that has a clinical value and that can be integrated into the current response assessment of the International Myeloma Working Group for patients with Myeloma.

This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.